BR112014019155A8 - Comprimido antiácido - Google Patents

Comprimido antiácido

Info

Publication number
BR112014019155A8
BR112014019155A8 BR112014019155A BR112014019155A BR112014019155A8 BR 112014019155 A8 BR112014019155 A8 BR 112014019155A8 BR 112014019155 A BR112014019155 A BR 112014019155A BR 112014019155 A BR112014019155 A BR 112014019155A BR 112014019155 A8 BR112014019155 A8 BR 112014019155A8
Authority
BR
Brazil
Prior art keywords
tablet
present
antacid tablet
oral antacid
antacid
Prior art date
Application number
BR112014019155A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014019155A2 (enExample
Inventor
S Mirabile Maria
G Shah Sandip
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112014019155A2 publication Critical patent/BR112014019155A2/pt
Publication of BR112014019155A8 publication Critical patent/BR112014019155A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014019155A 2012-02-02 2013-01-31 Comprimido antiácido BR112014019155A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594055P 2012-02-02 2012-02-02
PCT/US2013/024078 WO2013116477A1 (en) 2012-02-02 2013-01-31 Antacid tablet

Publications (2)

Publication Number Publication Date
BR112014019155A2 BR112014019155A2 (enExample) 2017-06-20
BR112014019155A8 true BR112014019155A8 (pt) 2017-07-11

Family

ID=48905820

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019155A BR112014019155A8 (pt) 2012-02-02 2013-01-31 Comprimido antiácido

Country Status (12)

Country Link
US (1) US20140037759A1 (enExample)
EP (1) EP2809331A4 (enExample)
CN (1) CN104136033A (enExample)
AR (1) AR089857A1 (enExample)
BR (1) BR112014019155A8 (enExample)
CA (1) CA2863389A1 (enExample)
CO (1) CO7020922A2 (enExample)
HK (1) HK1201179A1 (enExample)
IN (1) IN2014DN06198A (enExample)
MX (1) MX2014009391A (enExample)
WO (1) WO2013116477A1 (enExample)
ZA (1) ZA201405354B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025222289A1 (en) * 2024-04-23 2025-10-30 Biovantek Calcium carbonate formulations and method of treatment of gastroesophageal reflux disease (gerd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243567A (en) * 1991-07-22 1995-04-27 Bristol Myers Squibb Co Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
GB9825033D0 (en) * 1998-11-13 1999-01-13 Nycomed Pharma As Process
US6358526B1 (en) * 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
WO2004064719A2 (en) * 2003-01-24 2004-08-05 State Of Israel, Ministry Of Agriculture Synergistic compositions and methods for potentiating anti-oxidative activity
WO2004073632A2 (en) * 2003-02-19 2004-09-02 Biovail Laboratories Inc. Rapid absorption selective 5-ht agonist formulations
UA95093C2 (uk) * 2005-12-07 2011-07-11 Нікомед Фарма Ас Спосіб одержання кальцієвмісної сполуки
AR061093A1 (es) * 2006-05-12 2008-08-06 Drug Tech Corp Composiciones de calcio

Also Published As

Publication number Publication date
CN104136033A (zh) 2014-11-05
EP2809331A4 (en) 2015-07-15
WO2013116477A1 (en) 2013-08-08
CO7020922A2 (es) 2014-08-11
ZA201405354B (en) 2015-11-25
HK1201179A1 (en) 2015-08-28
AR089857A1 (es) 2014-09-24
MX2014009391A (es) 2014-08-27
BR112014019155A2 (enExample) 2017-06-20
EP2809331A1 (en) 2014-12-10
IN2014DN06198A (enExample) 2015-10-23
US20140037759A1 (en) 2014-02-06
CA2863389A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
BR112012025592A2 (pt) moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
IN2012MN02923A (enExample)
DK2315580T3 (da) Farmaceutiske formuleringer og fremgangsmåder til behandling af luftvejsinfektioner
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MY161088A (en) Agonists of gpr40
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
MX2009009153A (es) Pirano-pirazol-aminas.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12015500823A1 (en) Modified release formulations for oprozomib
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
BR112017001000A2 (pt) composições de açúcar para preparação de comprimidos por compressão direta
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2499 DE 27-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.